Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.

José Alejandro Pérez-FidalgoEva GuerraYolanda GarcíaMaría IglesiasMaría Hernández-SosaPurificación Estevez-GarcíaLuis Manso SánchezAna SantaballaAna OakninAndres RedondoM Jesús RubioAntonio González-Martín

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)

High neutrophil/lymphocyte ratio at platinum-resistant relapse indicated poor prognosis in patients treated with olaparib plus pegylated liposomal doxorubicin. A multifactorial clinical signature was more precise than single variables for implying the prognosis and may help in therapeutic assignment after further validation in large prospective cohorts.

Keyphrases

phase ii
poor prognosis
clinical trial
open label
long non coding rna
drug delivery
double blind
cancer therapy
phase iii
free survival
peripheral blood